1. History, current status, and future directions of artificial intelligence Olga Kubassova, Faiq Shaikh, Carlos Melus, and Michael Mahler 2. Precision medicine as an approach to autoimmune diseases Marvin J. Fritzler and Michael Mahler 3. Biomarker and data science as integral part of precision medicine Carlos Melus, Brenden Rossin, Mary Ann Aure, and Michael Mahler 4. Companion and complementary diagnostics: A key to precision medicine Jan Trøst Jørgensen 5. Checkpoint inhibitors: Interface of cancer and autoimmunity: Opportunity for second level precision medicine Savino Sciascia, Marie Hudson, Marvin J. Fritzler, Minoru Satoh, and Michael Mahler 6. The evolving potential of precision medicine in the management of autoimmune liver disease Gary L. Norman, Nicola Bizzaro, Danilo Villalta, Diego Vergani, Giorgina Mieli-Vergani, Gideon M. Hirschfield, and Michael Mahler 7. Precision medicine in autoimmune disease Kevin D. Deane 8. Development of multi-omics approach in autoimmune diseases May Y. Choi, Marvin J. Fritzler, and Michael Mahler 9. N-of-1 trials: Implications for clinical practice and personalized clinical trials Joanne Bradbury and Michael Mahler 10. Health risk assessment and family history: Toward disease prevention Lily W. Martin, Lauren C. Prisco, Laura Martinez-Prat, Michael Mahler, and Jeffrey A. Sparks 11. Regulatory aspects of artificial intelligence and machine learning-enabled software as medical devices (SaMD) Michael Mahler, Carolina Auza, Roger Albesa, Carlos Melus, and Jungen Andrew Wu 12. Precision medicine from the patient's perspective: More opportunities and increasing responsibilities Kim MacMartin-Moglia and Michael Mahler
Michael Mahler received his Ph.D. from the institute of molecular genetics at the University of Heidelberg (Germany). During his Ph.D. thesis, Michael Mahler worked at The Scripps Research Institute in the laboratory of Prof. Mike Pollard and Prof. Eng Tan. He is currently Vice President of Research at Inova Diagnostics. His research is focused on the B-cell autoimmune response in autoimmune diseases and the discovery of novel autoantigens which resulted in more than 300 peer reviewed journal articles as well as several patents. In addition, he works on the development and characterization of novel diagnostic assays for the diagnosis of autoimmune diseases. In the scientific community, he serves as Editor of different scientific journals and as reviewer for more than 40 journals. Michael Mahler became exposed to and interested in Artificial Intelligence as well as Precision Medicine and as a consequence, co-founded the Precision Medicine in Autoimmunity (PMA) (www.precisionmedicineautoimmunity.org) conference.